🔎 Trials Near Me

Gara Jalqabaatti › Myeloma Baay’ee › Colorado

Qorannoo klinikaalii Myeloma Baay’ee Colorado keessatti

Qorannoo 37 Myeloma Baay’ee f Colorado keessatti hirmaatuu jiru.

Magaalota Colorado keessatti

Takkalaa qorannoo (Ingiliffa)

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07589634

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

  • Local Institution - 0381, Aurora
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT05519085

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  • Research Site, Denver
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT07391657

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

  • Colorado Blood Cancer Institute /ID# 280275, Denver
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT07409246

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05652335

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07258511

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07518186

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06500884

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • CBCI, Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07648264

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT04910568

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06297226

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

  • Colorado Blood Cancer Institute, Denver
  • Rocky Mountain Cancer Center, Denver
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT07637578

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

  • Research Site, Denver
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  • UCHealth Poudre Valley Hospital, Fort Collins
  • UCHealth Harmony, Fort Collins
  • UCHealth Greeley Hospital, Greeley
  • fi 3 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • Penrose-Saint Francis Healthcare, Colorado Springs
  • Rocky Mountain Cancer Centers-Penrose, Colorado Springs
  • Saint Francis Cancer Center, Colorado Springs
  • fi 3 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT04566328

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

  • Colorado Blood Cancer Institute/SCRI, Denver
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT06292780

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Aurora
  • Research Site, Denver
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, Aurora
  • Research Site, Denver
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Hag-2026 · NCT07764978

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  • Colorado Blood Cancer Institute /ID# 273129, Denver
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ado-2026 · NCT06892522

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ado-2026 · NCT05469893

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Rocky Mountain Cancer Centers - Aurora /ID# 268574, Aurora
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT05650632

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  • UCHealth Poudre Valley Hospital, Fort Collins
  • UCHealth Harmony, Fort Collins
  • UCHealth Greeley Hospital, Greeley
  • fi 3 dabalataa
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Ado-2026 · NCT06057402

Integrated Cancer Repository for Cancer Research

  • Advent Health, Greenwood Village
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 19 hanga 110 · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT02012699

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Rocky Mountain Regional VA Medical Center, Aurora
  • Penrose-Saint Francis Healthcare, Colorado Springs
  • Rocky Mountain Cancer Centers-Penrose, Colorado Springs
  • fi 6 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin hundi · Saalaa hunda · Haaromfame 10-Wax-2026 · NCT05561387

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  • University of Colorado Hospital, Aurora
  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Wax-2026 · NCT05243797

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 19 fi ol · Saalaa hunda · Haaromfame 04-Wax-2026 · NCT06974786

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  • Colorado Blood Cancer Institute/SCRI, Denver
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Cam-2026 · NCT05828511

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

  • Colorado Blood Cancer Institute, Denver
  • Rocky Mountain Cancer Center, Denver
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Elb-2026 · NCT05972135

Survivors Uniting for Remote Guided Exercise

  • Human Performance Clinical Research Lab, Fort Collins
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 31-Bit-2026 · NCT07290309

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 24-Bit-2026 · NCT04988555

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  • Colorado Blood Cancer Institute, Denver
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Bit-2026 · NCT06153251

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

  • CU Anschutz Medical Campus, Anshutz Cancer Pavillion, Aurora
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2025 · NCT05722418

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.